Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here is one stock where Wall Street’s excitement appears well-founded and two where analysts may be overlooking some important risks.
Two stocks to sell:
Onterris (ONT)
Consensus price target: $18.20 (22.7% implied return)
Founded to protect a tree-lined two-lane road, Onterris (NYSE: ONT) provides air quality monitoring, environmental laboratory testing, compliance, and environmental consulting services.
Why Is ONT Not Exciting?
- Sales are projected to remain flat over the next 12 months as demand decelerates from its two-year trend
- Historical operating margin losses point to an inefficient cost structure
- Negative returns on capital show management lost money while trying to expand the business
Onterris’s stock price of $14.84 implies a valuation ratio of 10.3x forward P/E. Read our free research report to see why you should think twice about including ONT in your portfolio.
PacBio (PACB)
Consensus price target: $2.54 (13% implied return)
Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ: PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.
Why Are We Wary of PACB?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 8.2% annually over the last two years
- Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
- Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders
PacBio is trading at $2.25 per share, or 3.9x forward price-to-sales. To fully understand why you should be careful with PACB, check out our full research report (it’s free).
One stock to buy:
Micron (MU)
Consensus price target: $1,562 (71% implied return)
Founded in the basement of a Boise, Idaho dental office in 1978, Micron (NASDAQ: MU) is a leading provider of memory chips used in thousands of devices across mobile, data centers, industrial, consumer, and automotive markets.
Why Is MU a Good Business?
- Impressive 130% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Incremental sales over the last five years have been highly profitable as its earnings per share increased by 65.6% annually, topping its revenue gains
- Strong free cash flow margin of 35.5% enables it to reinvest or return capital consistently, and its improved cash conversion implies it’s becoming a less capital-intensive business
At $913.25 per share, Micron trades at 5x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks we like even more
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
